Ngozi Essandoh, MD
Internal Medicine · Baltimore, MDNPI 1053547745
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 81 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Novartis at 27.8% of the total. Reporting peaked in 2020 at $370 and has fallen 63.7% since, to $134 in 2025.
Across 81 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$452
- Johnson & Johnson$369
- Pfizer$199
- E.r. Squibb & Sons, L.L.C.$114
- Gilead$84
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$80
- plus $328 from 10 others
What the payments were for
- Food & beverage$1,627100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 27 | $452 |
| Johnson & Johnson(2 entities) | 16 | $369 |
| Pfizer | 9 | $199 |
| E.r. Squibb & Sons, L.L.C. | 8 | $114 |
| Gilead | 3 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $80 |
| AstraZeneca(2 entities) | 3 | $73 |
| AbbVie | 3 | $63 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $61 |
| Chiesi USA, Inc. | 1 | $25 |
| GSK | 1 | $22 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Melinta Therapeutics, LLC | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Mylan Specialty L.p. | 1 | $14 |
| Portola Pharmaceuticals, LLC | 1 | $13 |
How this compares
$1,627 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Pantoprazole Sodium | 11 | $93 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Baltimore
- Param DedhiaBaltimore$636K
- Shawn DhillonBaltimore$227K
- Jeremy SugarmanBaltimore$210K
- Charles FlexnerBaltimore$133K
- Kristen MarroneBaltimore$97K
- Ana-Maria OrbaiBaltimore$89K
- Mark YarchoanBaltimore$89K
- David Muniz PedrogoBaltimore$82K
- Julie PaikBaltimore$76K
- Allison AgwuBaltimore$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.